关注
Francisco J. Esteva
Francisco J. Esteva
Chief, Breast Medical Oncology, Northwell Health Cancer Institute at Lenox Hill Hospital
在 northwell.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ...
Cancer cell 6 (2), 117-127, 2004
22562004
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
R Nahta, D Yu, MC Hung, GN Hortobagyi, FJ Esteva
Nature clinical practice Oncology 3 (5), 269-280, 2006
11952006
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
9802018
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta, LXH Yuan, B Zhang, R Kobayashi, FJ Esteva
Cancer research 65 (23), 11118-11128, 2005
9642005
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ...
Clinical chemistry 54 (12), e11-e79, 2008
841*2008
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta, MC Hung, FJ Esteva
Cancer research 64 (7), 2343-2346, 2004
7992004
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ...
Journal of Clinical Oncology 19 (10), 2587-2595, 2001
7502001
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
7492002
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
New england Journal of medicine 382 (6), 514-524, 2020
6792020
Planning cancer control in Latin America and the Caribbean
PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ...
The lancet oncology 14 (5), 391-436, 2013
6322013
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ...
Nature medicine 17 (4), 461-469, 2011
6152011
Herceptin: mechanisms of action and resistance
R Nahta, FJ Esteva
Cancer letters 232 (2), 123-138, 2006
6102006
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615-2623, 2012
6052012
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
6002007
HER2 therapy: molecular mechanisms of trastuzumab resistance
R Nahta, FJ Esteva
Breast Cancer Research 8, 1-8, 2006
5612006
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience
V Guarneri, DJ Lenihan, V Valero, JB Durand, K Broglio, KR Hess, ...
Journal of Clinical Oncology 24 (25), 4107-4115, 2006
4632006
Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline
SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ...
Journal of clinical oncology 32 (19), 2078-2099, 2014
4542014
Residual risk of breast cancer recurrence 5 years after adjuvant therapy
AM Brewster, GN Hortobagyi, KR Broglio, SW Kau, CA Santa-Maria, ...
Journal of the National Cancer Institute 100 (16), 1179-1183, 2008
4532008
Trastuzumab: triumphs and tribulations
RE Nahta, FJ Esteva
Oncogene 26 (25), 3637-3643, 2007
4312007
Immunotherapy and targeted therapy combinations in metastatic breast cancer
FJ Esteva, VM Hubbard-Lucey, J Tang, L Pusztai
The lancet oncology 20 (3), e175-e186, 2019
4232019
系统目前无法执行此操作,请稍后再试。
文章 1–20